{
  "docId": "019de076-8fd6-709e-8689-4f849e880c13",
  "docSlug": "045f5237a1062f1479093c113a295dbd",
  "documentTitle": "Alkermes | Investor Conference Presentation Deck | 29 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 29,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-8fd6-709e-8689-4f849e880c13/4",
  "deckHref": "/decks/019de076-8fd6-709e-8689-4f849e880c13",
  "deckJsonHref": "/decks/019de076-8fd6-709e-8689-4f849e880c13.json",
  "deckAnchorHref": "/decks/019de076-8fd6-709e-8689-4f849e880c13#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.8,
        "x": 0.1,
        "y": 0.25
      },
      "kind": "list",
      "text": "Prevailed in Janssen arbitration; Raised 2023 financial expectations\nSuccessfully settled VIVITROL® patent litigation\nGenerated ALKS 2680 initial clinical proof-of-concept data in patients with narcolepsy type 1\nCompleted separation of the oncology business\nContinued focus on operational efficiency including recent agreement to divest Athlone, Ireland manufacturing facility\nGrew proprietary commercial product portfolio net sales by 20%* year-over-year",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72ad6bdc-62c9-4b17-9231-2439fa292b49",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.05,
        "y": 0.89
      },
      "kind": "source-note",
      "text": "*Based on nine months ended Sept. 30, 2023 compared to the same period in the prior year",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c447369-2622-4cf7-b09c-b35cfbc836a7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.07
      },
      "kind": "title",
      "text": "2023 Accomplishments Enabled Repositioning of Alkermes and Established Strong Foundation for Growth",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2c6b1b59-33b4-4f17-a107-101f48f4e950",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 13,
      "from": 4,
      "beatId": "5e80849a-633e-442e-8184-8e15f41fe45c",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Evidence",
      "beatSlug": "evidence",
      "evidence": "The deck presents evidence of Alkermes' growth trends and commercial performance.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}